Abstract
Objective To investigate the effect of triple chemotherapy including bacillus calmette guerin (BCG) and hydroxycamptothecin (HCPT) and pirarubicin (THP) with bladder perfusion on recurrence risk, survival time and laboratory parameters of patients with superficial bladder cancer after (transurethral resection of bladder cancer, TURBT). Methods A total of 130 patients with superficial bladder cancer after TURBT were chosen from January 2011 to August 2013 in our hospital and randomly divided into two groups, control group with HCPT+ THP and observation group with BCG+ HCPT+ THP, 65 cases each group. and the recurrence rate with follow-up, the long-term survival rate, the levels of tumor marker and vascular endothelial growth factor (VEGF) and adverse reaction incidence of both groups were compared between two groups. Results The recurrence rate with follow-up of observation group was significantly lower than control group(P 0.05). Conclusions Triple chemotherapy with bladder perfusion on recurrence risk, survival time and laboratory parameters of patients with superficial bladder cancer after TURBT can efficiently reduce the recurrence risk, prolong the survival time, down-regulate the levels of tumor markers and VEGF and not increase the risk of adverse reactions. Key words: Urinary Bladder Neoplasms; Neoplasm Recurrence, Local; BCG Vaccine; Camptothecin
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
